Keros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Keros Therapeutics (NASDAQ:KROS) issued its earnings results on Thursday. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.05), FiscalAI reports. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million.

Keros Therapeutics Trading Down 8.3%

Shares of Keros Therapeutics stock opened at $10.99 on Friday. The company’s fifty day simple moving average is $11.50 and its two-hundred day simple moving average is $15.75. The company has a market cap of $217.49 million, a P/E ratio of 6.04 and a beta of 0.95. Keros Therapeutics has a 12-month low of $10.32 and a 12-month high of $22.55.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the period. New York State Common Retirement Fund grew its position in shares of Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the period. Sherbrooke Park Advisers LLC purchased a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $176,000. Finally, XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics in the 4th quarter worth about $212,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KROS. Wall Street Zen downgraded shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.40.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.